![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD48 |
Gene summary for CD48 |
![]() |
Gene information | Species | Human | Gene symbol | CD48 | Gene ID | 962 |
Gene name | CD48 molecule | |
Gene Alias | BCM1 | |
Cytomap | 1q23.3 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A087X1S7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
962 | CD48 | C21 | Human | Oral cavity | OSCC | 1.54e-05 | 2.22e-01 | 0.2678 |
962 | CD48 | C30 | Human | Oral cavity | OSCC | 5.55e-04 | 2.22e-01 | 0.3055 |
962 | CD48 | C57 | Human | Oral cavity | OSCC | 9.26e-03 | 2.18e-01 | 0.1679 |
962 | CD48 | C06 | Human | Oral cavity | OSCC | 1.31e-02 | 6.19e-01 | 0.2699 |
962 | CD48 | LN46 | Human | Oral cavity | OSCC | 6.26e-06 | 3.61e-01 | 0.1666 |
962 | CD48 | EOLP-1 | Human | Oral cavity | EOLP | 1.81e-09 | 3.50e-01 | -0.0202 |
962 | CD48 | EOLP-2 | Human | Oral cavity | EOLP | 4.65e-15 | 4.57e-01 | -0.0203 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
GO:004211023 | Oral cavity | EOLP | T cell activation | 111/2218 | 487/18723 | 4.67e-12 | 8.17e-10 | 111 |
GO:00028193 | Oral cavity | EOLP | regulation of adaptive immune response | 38/2218 | 183/18723 | 3.75e-04 | 3.40e-03 | 38 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04650 | Oral cavity | EOLP | Natural killer cell mediated cytotoxicity | 38/1218 | 132/8465 | 1.26e-05 | 7.01e-05 | 4.13e-05 | 38 |
hsa046501 | Oral cavity | EOLP | Natural killer cell mediated cytotoxicity | 38/1218 | 132/8465 | 1.26e-05 | 7.01e-05 | 4.13e-05 | 38 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CD48 | CD244 | CD48_CD244A | CD48 | CRC | AD |
CD48 | CD244 | CD48_CD244A | CD48 | CRC | MSI-H |
CD48 | CD244 | CD48_CD244A | CD48 | CRC | SER |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD48 | SNV | Missense_Mutation | novel | c.342G>T | p.Lys114Asn | p.K114N | protein_coding | tolerated(0.24) | benign(0.2) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD48 | SNV | Missense_Mutation | novel | c.272N>A | p.Ser91Asn | p.S91N | protein_coding | tolerated(0.38) | probably_damaging(0.99) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
CD48 | deletion | Frame_Shift_Del | novel | c.508delA | p.Arg170GlyfsTer33 | p.R170Gfs*33 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
CD48 | SNV | Missense_Mutation | novel | c.571N>A | p.Ser191Thr | p.S191T | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
CD48 | SNV | Missense_Mutation | c.195N>T | p.Lys65Asn | p.K65N | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CD48 | SNV | Missense_Mutation | rs372863860 | c.103G>A | p.Val35Met | p.V35M | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-AX-A3G6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD48 | SNV | Missense_Mutation | c.91N>A | p.Val31Ile | p.V31I | protein_coding | tolerated(0.2) | benign(0.017) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
CD48 | SNV | Missense_Mutation | rs372863860 | c.103N>A | p.Val35Met | p.V35M | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
CD48 | SNV | Missense_Mutation | novel | c.713N>T | p.Arg238Ile | p.R238I | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.905) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
CD48 | SNV | Missense_Mutation | novel | c.686N>C | p.Gln229Pro | p.Q229P | protein_coding | deleterious_low_confidence(0.04) | benign(0.073) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |